Finvector Vision Therapies

Executive Summary

FinVector Vision Therapies is a Finnish contract development and manufacturing organization (CDMO) specialized in cGMP production of viral-based gene therapy products. Leveraging over 30 years of collective expertise, the company operates a state-of-the-art facility in Kuopio, Finland. FinVector currently markets a commercial product for non-muscle invasive bladder cancer and serves clients developing gene therapies for chronic ophthalmic conditions. Its core capabilities include process development, analytical testing, and large-scale viral vector manufacturing.

Upcoming Catalysts (preview)

• Q3 2026Signing of a major multi-year gene therapy CDMO contract70% success
• TBDExpansion of Kuopio manufacturing facility to increase viral vector capacity80% success
• Q1 2027Announcement of a strategic partnership for ophthalmic gene therapy60% success